Literature DB >> 14660729

Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs.

Jeffrey L Schwartz1, Yasuko Tamura, Robert Jordan, John R Grierson, Kenneth A Krohn.   

Abstract

UNLABELLED: The use of radiolabeled thymidine (TdR) and thymidine analogs as PET-based tracers of tumor growth rate is based on the assumption that measurement of uptake of these nucleosides, a function primarily of thymidine kinase-1 (TK(1)) activity, provides an accurate measure of active cell proliferation in tumors. The goal of this study was to test this hypothesis and determine how well these tracers track changes in proliferation of tumor cells.
METHODS: TK(1) activity; S-phase fraction; and uptake of TdR, 3'-deoxy-3'-fluorothymidine (FLT), and 2'-fluoro-5-methyl-1-(beta-D-2-arabino-furanosyl) uracil (FMAU) were determined in plateau-phase and exponentially growing cultures of 3 human and 3 murine tumor cell lines.
RESULTS: TK(1) activity and S-phase fraction increased in all cell lines as cells moved from plateau-phase conditions to exponential growth. Some cell lines had relatively large TK(1) activities and S-phase fractions under plateau-phase conditions, consistent with a loss of normal cell cycle checkpoint control in these cells. There were also 2 cell lines in which TK(1) activity changed little as cells moved from the plateau phase to exponential growth, suggesting that in these cell lines, de novo nucleotide synthesis pathways predominate over salvage pathways. Both TdR and FLT detected changes in TK(1) activity. The slope of the relationship between TdR uptake and TK(1) activity was nearly twice that for FLT and more than 40-fold that for FMAU.
CONCLUSION: Although not all tumors show a strong TK(1) dependence of proliferation, in all cell lines for which proliferation is highly TK(1) dependent, phosphorylation of TdR or FLT accurately reflects changes in TK(1) enzyme activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14660729

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  42 in total

1.  Noninvasive imaging of endogenous neural stem cell mobilization in vivo using positron emission tomography.

Authors:  Maria Adele Rueger; Heiko Backes; Maureen Walberer; Bernd Neumaier; Roland Ullrich; Marie-Lune Simard; Beata Emig; Gereon Rudolf Fink; Mathias Hoehn; Rudolf Graf; Michael Schroeter
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

2.  Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer.

Authors:  Wenfeng Yang; Yongming Zhang; Zheng Fu; Jinming Yu; Xiaorong Sun; Dianbin Mu; Anqin Han
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-23       Impact factor: 9.236

3.  Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells.

Authors:  David A Plotnik; Lindsay E Emerick; Kenneth A Krohn; Jashvant D Unadkat; Jeffrey L Schwartz
Journal:  J Nucl Med       Date:  2010-08-18       Impact factor: 10.057

Review 4.  [18F]FLT-PET in oncology: current status and opportunities.

Authors:  Lukas B Been; Albert J H Suurmeijer; David C P Cobben; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12       Impact factor: 9.236

Review 5.  Development of molecular probes for imaging sigma-2 receptors in vitro and in vivo.

Authors:  Robert Henry Mach; Kenneth Theodore Wheeler
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2009-09

6.  Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer.

Authors:  Seung Jin Lee; Jeong Seok Yeo; Haeng Jung Lee; Eun Jung Lee; Seog Young Kim; Se Jin Jang; Jong Jin Lee; Jin-Sook Ryu; Dae Hyuk Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

Review 7.  Novel Approaches to Imaging Tumor Metabolism.

Authors:  Sui-Seng Tee; Kayvan R Keshari
Journal:  Cancer J       Date:  2015 May-Jun       Impact factor: 3.360

8.  Evaluation of 3'-deoxy-3'-[18F]-fluorothymidine (18F-FLT) kinetics correlated with thymidine kinase-1 expression and cell proliferation in newly diagnosed gliomas.

Authors:  Aya Shinomiya; Nobuyuki Kawai; Masaki Okada; Keisuke Miyake; Takehiro Nakamura; Yoshio Kushida; Reiji Haba; Nobuyuki Kudomi; Yuka Yamamoto; Masaaki Tokuda; Takashi Tamiya
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-15       Impact factor: 9.236

9.  Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET.

Authors:  Reiko Kameyama; Yuka Yamamoto; Kunihiko Izuishi; Ryusuke Takebayashi; Masanobu Hagiike; Makiko Murota; Masato Kaji; Reiji Haba; Yoshihiro Nishiyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-05       Impact factor: 9.236

10.  Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.

Authors:  David M Atkinson; Michelle J Clarke; Ann C Mladek; Brett L Carlson; David P Trump; Mark S Jacobson; Brad J Kemp; Val J Lowe; Jann N Sarkaria
Journal:  Head Neck       Date:  2008-06       Impact factor: 3.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.